Any news regarding weight loss drugs continues to be extremely popular, and Novo Nordisk’s major update was the resounding No. 1 release on prnewswire.com last month.
What Works
There’s a lot to convey in the headline, and it subsequently exceeds the ideal length, but the keyword strategy works.
There’s a version of this headline that reads something like “Novo Nordisk lowers cost of Wegovy® (semaglutide) to $499 per month” with the name of the new pharmacy and other features and descriptors in a subheadline or two. But if you’re writing releases for a publicly traded pharma company, you know the odds of the dozen people who have to sign off on the copy approving a headline under 70 characters are extremely low.
So, take note of Novo Nordisk’s approach here, incorporating multiple keywords and key phrases that resonate with its target audience, as well as the eye-catching number. Patients/potential patients searching for “Wegovy cost” or “lowering Wegovy cost” will find the PR Newswire version of this release on Page 1 of search results, along with plenty of earned media coverage about the news.
Bulleted subheadlines with critical data quickly convey the most important information and naturally draw a reader’s eye. Norvo Nordisk also weaves key data points throughout paragraphs in the body of the release, helping those stand out to readers who are skimming the content, and the two most important links for patients are featured well before all the boilerplate legal copy.